#1 Clinical Trials Search in Europe

Monalizumab

Monalizumab is an innovative drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the use of Monalizumab in clinical trials, focusing on its mechanisms, applications, and potential benefits in cancer therapy. The trials investigate Monalizumab alone and in combination with other drugs, providing valuable insights into its efficacy and safety profile across multiple cancer types.

Table of Contents

What is Monalizumab?

Monalizumab is an innovative immunotherapy drug being studied for the treatment of various types of cancer. It is also known by its research names IPH2201 and Anti-NKG2A[2]. Monalizumab is a type of medication called a monoclonal antibody, which means it’s a laboratory-made protein designed to target specific cells in the body[1].

How Does Monalizumab Work?

Monalizumab works by targeting and blocking a protein called CD94/NKG2A. This protein is found on certain immune cells, including Natural Killer (NK) cells and some types of T cells. By blocking CD94/NKG2A, monalizumab helps to enhance the anti-tumor functions of these immune cells, including their ability to attack and kill cancer cells[1].

In simpler terms, monalizumab acts like a key that unlocks the power of your immune system, allowing it to better recognize and fight cancer cells in your body.

What Conditions Does Monalizumab Treat?

Monalizumab is being studied for the treatment of several types of cancer, including:

  • Chronic Lymphocytic Leukemia (CLL): A type of blood cancer affecting white blood cells[2]
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer[3]
  • Small Cell Lung Cancer (SCLC): A less common but aggressive type of lung cancer[4]
  • Head and Neck Squamous Cell Carcinoma (SCCHN): Cancers that start in the mouth, nose, or throat[5]
  • Colorectal Cancer (CRC): Cancer that starts in the colon or rectum[6]
  • Esophageal and Gastroesophageal Junction Cancer: Cancers affecting the tube that connects the throat to the stomach[7]

Monalizumab in Clinical Trials

Monalizumab is currently being tested in various clinical trials to determine its safety and effectiveness. These trials are at different stages, ranging from early Phase 1 studies to more advanced Phase 3 trials[8][5].

In these trials, researchers are looking at several important factors:

  • Safety: How well patients tolerate the drug and what side effects may occur
  • Efficacy: How effective the drug is at treating cancer, often measured by tumor shrinkage or how long patients live without their cancer getting worse
  • Dosing: Finding the right amount and schedule for giving the drug
  • Combinations: How monalizumab works when combined with other cancer treatments

Combination Therapies with Monalizumab

Many of the clinical trials are studying monalizumab in combination with other cancer treatments. Some notable combinations include:

  • Monalizumab + Durvalumab: Durvalumab is another immunotherapy drug. This combination is being tested in lung cancer and other solid tumors[3][8].
  • Monalizumab + Cetuximab: Cetuximab is a targeted therapy. This combination is being studied in head and neck cancers[5].
  • Monalizumab + Ibrutinib: Ibrutinib is a drug used to treat certain blood cancers. This combination is being tested in chronic lymphocytic leukemia[2].
  • Monalizumab + Chemotherapy + Durvalumab: This triple combination is being studied in small cell lung cancer[4].

Potential Side Effects

As with all medications, monalizumab may cause side effects. In clinical trials, researchers carefully monitor patients for any adverse events. Common side effects observed in cancer treatments may include fatigue, nausea, and decreased appetite. However, the specific side effects of monalizumab are still being studied and may vary depending on the type of cancer and other treatments given alongside it[5].

It’s important to note that not everyone experiences side effects, and they can vary from person to person. If you’re participating in a clinical trial or receiving treatment with monalizumab, your healthcare team will closely monitor you and help manage any side effects that may occur.

Future Prospects for Monalizumab

The research on monalizumab is ongoing, and scientists are hopeful about its potential. If the clinical trials show positive results, monalizumab could become an important new tool in cancer treatment. It may offer new options for patients who have not responded well to other treatments or could be used in combination with existing therapies to improve outcomes[6].

As research continues, we may learn more about which patients are most likely to benefit from monalizumab and how best to use it in cancer treatment. The goal is to provide more effective and personalized treatment options for cancer patients in the future.

Aspect Details
Main Cancer Types Studied Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma (SCCHN), Colorectal cancer (CRC), Hematologic malignancies
Common Combination Therapies Durvalumab, Cetuximab, Chemotherapy regimens (e.g., platinum-based)
Dosage in Trials Typically 750 mg every 2 weeks or 1500 mg every 4 weeks, intravenously
Primary Outcomes Measured Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), Safety and tolerability
Mechanism of Action Blocks CD94/NKG2A receptor on NK cells and T cells, potentially enhancing anti-tumor activity
Notable Trial Designs Phase 1/2 dose escalation and expansion, Phase 3 randomized controlled trials
Biomarkers of Interest PD-L1 expression, HLA-E expression, Microsatellite status
Safety Considerations Monitoring for immune-related adverse events, dose-limiting toxicities

FAQ

  • What is Monalizumab and how does it work? Monalizumab is a humanized antibody that targets the CD94/NKG2A receptor. It works by blocking this inhibitory receptor on natural killer (NK) cells and T cells, potentially enhancing their anti-tumor functions and cytolytic activity against cancer cells.
  • In which types of cancer is Monalizumab being studied? Monalizumab is being studied in various cancer types, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (SCCHN), colorectal cancer (CRC), and other solid tumors. It's also being investigated in hematologic malignancies.
  • How is Monalizumab typically administered in clinical trials? In most trials, Monalizumab is administered intravenously (IV). The dosage and frequency can vary, but common regimens include 750 mg every two weeks or 1500 mg every four weeks, often in combination with other cancer treatments.
  • What are some common combination therapies being tested with Monalizumab? Monalizumab is frequently studied in combination with other drugs such as Durvalumab (an anti-PD-L1 antibody), cetuximab, and various chemotherapy regimens. These combinations aim to enhance the overall anti-tumor response.
  • What are the primary outcomes being measured in Monalizumab clinical trials? The primary outcomes often include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety assessments. Researchers also look at duration of response, disease control rate, and various biomarkers to evaluate Monalizumab's efficacy.

Ongoing Clinical Trials on Monalizumab

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

  • Study of Monalizumab for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Haploidentical Transplantation

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Ceralasertib, Oleclumab, and Monalizumab for Advanced Non-Small Cell Lung Cancer Patients Resistant to PD-1 Inhibitors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Portugal Spain

  • Study of Monalizumab and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer Previously Treated with an Immune Checkpoint Inhibitor

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Monalizumab: A humanized antibody that targets the CD94/NKG2A receptor on natural killer cells and T cells, potentially enhancing their anti-tumor functions.
  • Natural Killer (NK) cells: A type of immune cell that plays a crucial role in the body's defense against cancer and viral infections.
  • CD94/NKG2A receptor: An inhibitory receptor found on NK cells and some T cells that, when activated, can suppress their anti-tumor activity.
  • Durvalumab: An immunotherapy drug that blocks the PD-L1 protein, helping the immune system recognize and attack cancer cells.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Anti-Drug Antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can affect its efficacy and safety.
  • Concurrent Chemoradiation (cCRT): A treatment approach that combines chemotherapy and radiation therapy given at the same time.
  • Microsatellite Stable (MSS): A characteristic of tumors that do not have high levels of genetic instability in microsatellite regions of DNA.
  • HLA-E: Human Leukocyte Antigen-E, a protein involved in immune regulation and a ligand for the NKG2A receptor.

References

  1. https://clinicaltrials.gov/study/NCT02921685
  2. https://clinicaltrials.gov/study/NCT02557516
  3. https://clinicaltrials.gov/study/NCT05221840
  4. https://clinicaltrials.gov/study/NCT05903092
  5. https://clinicaltrials.eu/trial/study-of-monalizumab-and-cetuximab-for-patients-with-recurrent-or-metastatic-head-and-neck-cancer-previously-treated-with-an-immune-checkpoint-inhibitor/
  6. https://clinicaltrials.gov/study/NCT06152523
  7. https://clinicaltrials.gov/study/NCT03307941
  8. https://clinicaltrials.gov/study/NCT02671435